Roles and potential therapeutic targets of the ubiquitin proteasome system in muscle wasting

BMC Biochemistry

Volumn 8, Issue SUPPL. 1, 2007, Pages

  Nury, David ^a   Doucet, Christine ^b   Coux, Olivier ^a  

^a Centre National de la Recherche Scientifique   (France)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA HYDROXY BETA METHYLBUTYRIC ACID; BORTEZOMIB; BUTYRIC ACID DERIVATIVE; CLENBUTEROL; FENOTEROL; FORMOTEROL; IBUPROFEN; ICOSAPENTAENOIC ACID; PENTOXIFYLLINE; PR 171; PROTEASOME; PROTEASOME INHIBITOR; RESVERATROL; SALINOSPORAMIDE A; THALIDOMIDE; TORBAFYLLINE; UBIQUITIN; ENZYME INHIBITOR; UBIQUITIN PROTEIN LIGASE;

CACHEXIA; DRUG MECHANISM; DRUG TARGETING; HUMAN; HYPOKALEMIA; MULTIPLE MYELOMA; MUSCLE ATROPHY; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TACHYCARDIA; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; ENZYMOLOGY; METABOLISM; METHODOLOGY;

ANIMALS; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HUMANS; MUSCULAR ATROPHY; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN-PROTEIN LIGASE COMPLEXES;

EID: 38449101649     PISSN: None     EISSN: 14712091     Source Type: Journal    
DOI: 10.1186/1471-2091-8-S1-S7     Document Type: Review

References (116)

1. Intracellular signaling during skeletal muscle atrophy. SC Kandarian RW Jackman, Muscle Nerve 2006 33 155 165 10.1002/mus.20442 16228971
2. Lysosomal proteolysis in skeletal muscle. D Bechet A Tassa D Taillandier L Combaret D Attaix, Int J Biochem Cell Biol 2005 37 2098 2114 10.1016/j.biocel.2005.02.029 16125113
3. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. WE Mitch AL Goldberg, N Engl J Med 1996 335 1897 1905 10.1056/NEJM199612193352507 8948566
4. Ubiquitin-proteasome-dependent proteolysis in skeletal muscle. D Attaix E Aurousseau L Combaret A Kee D Larbaud C Ralliere B Souweine D Taillandier T Tilignac, Reprod Nutr Dev 1998 38 153 165 10.1051/rnd:19980202 9638789
5. The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting. MJ Tisdale, J Support Oncol 2005 3 209 217 15915823
6. The ubiquitin-proteasome system and skeletal muscle wasting. D Attaix S Ventadour A Codran D Bechet D Taillandier L Combaret, Essays Biochem 2005 41 173 186 16250905
7. Cachexia: pathophysiology and clinical relevance. JE Morley DR Thomas MM Wilson, Am J Clin Nutr 2006 83 735 743 16600922
8. Control of ubiquitination in skeletal muscle wasting. SS Wing, Int J Biochem Cell Biol 2005 37 2075 2087 10.1016/j.biocel.2004.11.011 16125111
9. Skeletal muscle hypertrophy and atrophy signaling pathways. DJ Glass, Int J Biochem Cell Biol 2005 37 1974 1984 16087388
10. Protein degradation by the ubiquitin-proteasome pathway in normal and disease States. SH Lecker AL Goldberg WE Mitch, J Am Soc Nephrol 2006 17 1807 1819 10.1681/ASN.2006010083 16738015
11. Insights into muscle atrophy and recovery pathway based on genetic models. TP Stein DR Bolster, Curr Opin Clin Nutr Metab Care 2006 9 395 402 16778568
12. Regulation of ATP-ubiquitin-dependent proteolysis in muscle wasting. D Attaix D Taillandier S Temparis D Larbaud E Aurousseau L Combaret L Voisin, Reprod Nutr Dev 1994 34 583 597 10.1051/rnd:19940605 7840873
13. A soluble, ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. J Etlinger AL Goldberg, Proc Natl Acad Sci USA 1977 74 54 58 264694 10.1073/pnas.74.1.54
14. Characterization of the heat-stable polypeptide of the ATP-dependent proteolytic system from reticulocytes. A Ciechanover S Elias H Heller S Ferber A Hershko, J Biol Chem 1980 255 7525 7528 6249802
15. A multicomponent system that degrades proteins conjugated to ubiquitin. Resolution of factors and evidence for ATP-dependent complex formation. D Ganoth E Leshinsky E Eytan A Hershko, J Biol Chem 1988 263 12412 12419 2842333
16. Proteolysis: from the lysosome to ubiquitin and the proteasome. A Ciechanover, Nat Rev Mol Cell Biol 2005 6 79 87 10.1038/nrm1552 15688069
17. Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. NE Tawa R Odessey AL Goldberg, J Clin Invest 1997 100 197 203 9202072
18. The ubiquitin system. A Hershko A Ciechanover, Annu Rev Biochem 1998 67 425 479 10.1146/annurev.biochem.67.1.425 9759494
19. Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. BA Schulman AC Carrano PD Jeffrey Z Bowen ER Kinnucan MS Finnin SJ Elledge JW Harper M Pagano NP Pavletich, Nature 2000 408 381 386 10.1038/35042620 11099048
20. Ubiquitin-protein ligases - novel therapeutic targets? PA Robinson, Curr Protein Pept Sci 2004 5 163 176 10.2174/1389203043379800 15180521
21. The 26S proteasome: a molecular machine designed for controlled proteolysis. D Voges P Zwickl W Baumeister, Annu Rev Biochem 1999 68 1015 1068 10.1146/annurev.biochem.68.1.1015 10872471
22. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. M Rechsteiner CP Hill, Trends Cell Biol 2005 15 27 33 10.1016/j.tcb.2004.11.003 15653075
23. Increased transcription of ubiquitin-proteasome system components: molecular responses associated with muscle atrophy. SR Price, Int J Biochem Cell Biol 2003 35 617 628 10.1016/S1357-2725(02)00385-0 12672454
24. Ubiquitin-protein ligases in muscle wasting: multiple parallel pathways? SH Lecker, Curr Opin Clin Nutr Metab Care 2003 6 271 275 10.1097/00075197- 200305000-00001 12690258
25. USP19 is a ubiquitin-specific protease regulated in rat skeletal muscle during catabolic states. L Combaret OA Adegoke N Bedard V Baracos D Attaix SS Wing, Am J Physiol Endocrinol Metab 2005 288 E693 700 10.1152/ajpendo.00281.2004 15562254
26. Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the N-end rule pathway. V Solomon V Baracos P Sarraf AL Goldberg, Proc Natl Acad Sci U S A 1998 95 12602 12607 9770532 10.1073/pnas.95.21.12602
27. Regulation of protein catabolism by muscle-specific and cytokine-inducible ubiquitin ligase E3{alpha}-II during cancer cachexia. KS Kwak X Zhou V Solomon VE Baracos J Davis AW Bannon WJ Boyle DL Lacey HQ Han, Cancer Res 2004 64 8193 8198 10.1158/0008-5472.CAN-04-2102 15548684
28. The ubiquitin system and the N-end rule pathway. A Varshavsky G Turner F Du Y Xie, Biol Chem 2000 381 779 789 10.1515/BC.2000.101 11076011
29. A family of mammalian E3 ubiquitin ligases that contain the UBR Box Motif and recognize N-degrons. T Tasaki LC Mulder A Iwamatsu MJ Lee IV Davydov A Varshavsky M Muesing YT Kwon, Mol Cell Biol 2005 25 7120 7136 16055722 10.1128/MCB.25.16.7120-7136.2005
30. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. MD Gomes SH Lecker RT Jagoe A Navon AL Goldberg, Proc Natl Acad Sci U S A 2001 98 14440 14445 11717410 10.1073/pnas.251541198
31. Identification of ubiquitin ligases required for skeletal muscle atrophy. SC Bodine E Latres S Baumhueter VK Lai L Nunez BA Clarke WT Poueymirou FJ Panaro E Na K Dharmarajan ZQ Pan DM Valenzuela TM DeChiara TN Stitt GD Yancopoulos DJ Glass, Science 2001 294 1704 1708 10.1126/science.1065874 11679633
32. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. HH Li V Kedar C Zhang H McDonough R Arya DZ Wang C Patterson, J Clin Invest 2004 114 1058 1071 15489953 10.1172/JCI200422220
33. MURF-1 and MURF-2 target a specific subset of myofibrillar proteins redundantly: towards understanding MURF-dependent muscle ubiquitination. SH Witt H Granzier CC Witt S Labeit, J Mol Biol 2005 350 713 722 10.1016/j.jmb.2005.05. 021 15967462
34. Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts. V Solomon AL Goldberg, J Biol Chem 1996 271 26690 26697 10.1074/jbc.271.41.25240 8900146
35. Calpains in muscle wasting. M Bartoli I Richard, Int J Biochem Cell Biol 2005 37 2115 2133 10.1016/j.biocel.2004.12.012 16125114
36. Ca(2+)-dependent proteolysis in muscle wasting. P Costelli P Reffo F Penna R Autelli G Bonelli FM Baccino, Int J Biochem Cell Biol 2005 37 2134 2146 10.1016/j.biocel.2005.03.010 15893952
37. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Du X Wang C Miereles JL Bailey R Debigare B Zheng SR Price WE Mitch, J Clin Invest 2004 113 115 123 14702115 10.1172/JCI200418330
38. Identification of cathepsin L as a differentially expressed message associated with skeletal muscle wasting. C Deval S Mordier C Obled D Bechet L Combaret D Attaix M Ferrara, Biochem J 2001 360 143 150 11696001 10.1042/0264-6021:3600143
39. Degradation of a cohesin subunit by the N-end rule pathway is essential for chromosome stability. H Rao F Uhlmann K Nasmyth A Varshavsky, Nature 2001 410 955 959 10.1038/35073627 11309624
40. Conditional expression of mutant M-line titins results in cardiomyopathy with altered sarcomere structure. M Gotthardt RE Hammer N Hubner J Monti CC Witt M McNabb JA Richardson H Granzier S Labeit J Herz, J Biol Chem 2003 278 6059 6065 10.1074/jbc.M211723200 12464612
41. A targeted deletion of the C-terminal end of titin, including the titin kinase domain, impairs myofibrillogenesis. G Miller H Musa M Gautel M Peckham, J Cell Sci 2003 116 4811 4819 10.1242/jcs.00768 14600266
42. Mechanically induced titin kinase activation studied by force-probe molecular dynamics simulations. F Grater J Shen H Jiang M Gautel H Grubmuller, Biophys J 2005 88 790 804 15531631 10.1529/biophysj.104.052423
43. Ubiquitin-binding domains. L Hicke HL Schubert CP Hill, Nat Rev Mol Cell Biol 2005 6 610 621 10.1038/nrm1701 16064137
44. The kinase domain of titin controls muscle gene expression and protein turnover. S Lange F Xiang A Yakovenko A Vihola P Hackman E Rostkova J Kristensen B Brandmeier G Franzen B Hedberg LG Gunnarsson SM Hughes S Marchand T Sejersen I Richard L Edstrom E Ehler B Udd M Gautel, Science 2005 308 1599 1603 10.1126/science.1110463 15802564
45. Glucocorticoids regulate mRNA levels for subunits of the 19 S regulatory complex of the 26 S proteasome in fast-twitch skeletal muscles. L Combaret D Taillandier D Dardevet D Bechet C Ralliere A Claustre J Grizard D Attaix, Biochem J 2004 378 239 246 14636157 10.1042/BJ20031660
46. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. M Sandri C Sandri A Gilbert C Skurk E Calabria A Picard K Walsh S Schiaffino SH Lecker AL Goldberg, Cell 2004 117 399 412 10.1016/S0092-8674(04)00400-3 15109499
47. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. TN Stitt D Drujan BA Clarke F Panaro Y Timofeyva WO Kline M Gonzalez GD Yancopoulos DJ Glass, Mol Cell 2004 14 395 403 10.1016/S1097-2765(04)00211-4 15125842
48. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. D Cai JD Frantz NE Tawa Jr PA Melendez BC Oh HG Lidov PO Hasselgren WR Frontera J Lee DJ Glass SE Shoelson, Cell 2004 119 285 298 10.1016/j.cell.2004.09.027 15479644
49. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. C Rommel SC Bodine BA Clarke R Rossman L Nunez TN Stitt GD Yancopoulos DJ Glass, Nat Cell Biol 2001 3 1009 1013 10.1038/ncb1101-1009 11715022
50. Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. KM Lai M Gonzalez WT Poueymirou WO Kline E Na E Zlotchenko TN Stitt AN Economides GD Yancopoulos DJ Glass, Mol Cell Biol 2004 24 9295 9304 15485899 10.1128/MCB.24.21.9295-9304.2004
51. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. JM Sacheck A Ohtsuka SC McLary AL Goldberg, Am J Physiol Endocrinol Metab 2004 287 E591 601 10.1152/ajpendo.00073.2004 15100091
52. Molecular determinants of skeletal muscle mass: getting the 'AKT' together. GA Nader, Int J Biochem Cell Biol 2005 37 1985 1996 10.1016/j.biocel.2005.02.026 16125108
53. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. SW Lee G Dai Z Hu X Wang J Du WE Mitch, J Am Soc Nephrol 2004 15 1537 1545 10.1097/01.ASN.0000127211.86206.E1 15153564
54. Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. JL Bailey B Zheng Z Hu SR Price WE Mitch, J Am Soc Nephrol 2006 17 1388 1394 10.1681/ASN.2004100842 16611720
55. IGF-1 is down-regulated in experimental cancer cachexia. P Costelli M Muscaritoli M Bossola F Penna P Reffo A Bonetto S Busquets G Bonelli FJ Lopez-Soriano GB Doglietto JM Argiles FM Baccino F Rossi Fanelli, Am J Physiol Regul Integr Comp Physiol 2006 291 R674 683 16614058
56. Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. X Wang Z Hu J Hu J Du WE Mitch, Endocrinology 2006 147 4160 4168 10.1210/en.2006-0251 16777975
57. Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. C McFarlane E Plummer M Thomas A Hennebry M Ashby N Ling H Smith M Sharma R Kambadur, J Cell Physiol 2006 209 501 514 10.1002/jcp.20757 16883577
58. Mysostatin regulation of muscle development: molecular basis, natural mutations, physiopathological aspects. D Joulia-Ekaza G Cabello, Exp Cell Res 2006 312 2401 2414 16793037
59. Signal-transduction networks and the regulation of muscle protein degradation. NJ Szewczyk LA Jacobson, Int J Biochem Cell Biol 2005 37 1997 2011 10.1016/j.biocel.2005.02.020 16125109
60. Ubiquitin signalling in the NF-kappaB pathway. ZJ Chen, Nat Cell Biol 2005 7 758 765 16056267 10.1038/ncb0805-758
61. Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model. I Kawamura R Morishita N Tomita E Lacey M Aketa S Tsujimoto T Manda M Tomoi I Kida J Higaki Y Kaneda K Shimomura T Ogihara, Gene Ther 1999 6 91 97 10.1038/sj.gt.3300819 10341880
62. Mechanism of muscle protein degradation induced by a cancer cachectic factor. MJ Lorite MG Thompson JL Drake G Carling MJ Tisdale, Br J Cancer 1998 78 850 856 (*First description of PIF) 9764574
63. Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). MJ Lorite HJ Smith JA Arnold A Morris MG Thompson MJ Tisdale, Br J Cancer 2001 85 297 302 10.1054/bjoc.2001.1879 11461093
64. NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle. SM Wyke MJ Tisdale, Br J Cancer 2005
65. Mechanism of induction of muscle protein degradation by angiotensin II. ST Russell SM Wyke MJ Tisdale, Cell Signal 2006 18 1087 1096 10.1016/j.cellsig.2005.09.009 16257180
66. Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy. RB Hunter E Stevenson A Koncarevic H Mitchell-Felton DA Essig SC Kandarian, Faseb J 2002 16 529 538 10.1096/fj.01-0866com 11919155
67. Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1. AS McElhinny K Kakinuma H Sorimachi S Labeit CC Gregorio, J Cell Biol 2002 157 125 136 10.1083/jcb.200108089 11927605
68. Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. V Kedar H McDonough R Arya HH Li HA Rockman C Patterson, Proc Natl Acad Sci U S A 2004 101 18135 18140 15601779 10.1073/pnas.0404341102
69. Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. LA Tintignac J Lagirand S Batonnet V Sirri MP Leibovitch SA Leibovitch, J Biol Chem 2005 280 2847 2856 10.1074/jbc.M411346200 15531760
70. Calcineurin controls nerve activity-dependent specification of slow skeletal muscle fibers but not muscle growth. AL Serrano M Murgia G Pallafacchina E Calabria P Coniglio T Lomo S Schiaffino, Proc Natl Acad Sci U S A 2001 98 13108 13113 11606756 10.1073/pnas.231148598
71. Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization. RC Langen JL Van Der Velden AM Schols MC Kelders EF Wouters YM Janssen-Heininger, Faseb J 2004 18 227 237 10.1096/fj.03-0251com 14769817
72. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. SH Lecker V Solomon WE Mitch AL Goldberg, J Nutr 1999 129 227S 237S 9915905
73. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. SH Lecker RT Jagoe A Gilbert M Gomes V Baracos J Bailey SR Price WE Mitch AL Goldberg, Faseb J 2004 18 39 51 10.1096/fj.03- 0610com 14718385
74. Ubiquitin-conjugating enzyme E2(14k)/HR6B is dispensable for increased protein catabolism in muscle of fasted mice. OA Adegoke N Bedard HP Roest SS Wing, Am J Physiol Endocrinol Metab 2002 283 E482 489 12169441
75. Construction and analysis of mouse strains lacking the ubiquitin ligase UBR1 (E3alpha) of the N-end rule pathway. YT Kwon Z Xia IV Davydov SH Lecker A Varshavsky, Mol Cell Biol 2001 21 8007 8021 11689692 10.1128/MCB.21.23.8007- 8021.2001
76. Effects of insulin glucose, and amino acids on protein turnover in rat diaphragm. RM Fulks JB Li AL Goldberg, J Biol Chem 1975 250 290 298 1141208
77. Developmental changes of the primary structure and histidine methylation in rabbit skeletal muscle myosin. G Huszar, Nat New Biol 1972 240 260 264 10.1038/240260a0 4512226
78. Ntau-methylhistidine (3-methylhistidine) and muscle protein turnover: an overview. VR Young HN Munro, Fed Proc 1978 37 2291 2300 350635
79. Gene therapy with anabolic growth factors to prevent muscle atrophy. O Schakman JP Thissen, Curr Opin Clin Nutr Metab Care 2006 9 207 213 16607118
80. Clinical anticachexia treatments. MJ Tisdale, Nutr Clin Pract 2006 21 168 174 16556927
81. Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. AS Whitehouse HJ Smith JL Drake MJ Tisdale, Cancer Res 2001 61 3604 3609 11325828
82. Thalidomide exerts its inhibitory action on tumous necrosis factor by enhancing mRNA degradation. AL Moreira EP Sampaio A Zmuidzinas P Frindt KA Smith G Kaplan, J Exp Med 1993 177 1675 1680 10.1084/jem.177.6.1675 8496685
83. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. JN Gordon TM Trebble RD Ellis HD Duncan T Johns PM Goggin, Gut 2005 54 540 545 10.1136/gut.2004.047563 15753541
84. On our way to targeted therapy for cachexia in cancer? MS Boddaert WR Gerritsen HM Pinedo, Curr Opin Oncol 2006 18 335 340 10.1097/01.cco.0000228738. 85626.ac 16721127
85. Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study. BJ Dezube ML Sherman JL Fridovich-Keil J Allen-Ryan AB Pardee, Cancer Immunol Immunother 1993 36 57 60 10.1007/BF01789132 7678547
86. Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats. L Combaret C Ralliere D Taillandier K Tanaka D Attaix, Mol Biol Rep 1999 26 95 101 10.1023/A:1006955832323 10363654
87. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. RM Goldberg CL Loprinzi JA Mailliard JR O'Fallon JE Krook C Ghosh RD Hestorff SF Chong NF Reuter TG Shanahan, J Clin Oncol 1995 13 2856 2859 7595749
88. Torbafylline (HWA 448) inhibits enhanced skeletal muscle ubiquitin- proteasome-dependent proteolysis in cancer and septic rats. L Combaret T Tilignac A Claustre L Voisin D Taillandier C Obled K Tanaka D Attaix, Biochem J 2002 361 185 192 11772390 10.1042/0264-6021:3610185
89. Clenbuterol induces muscle-specific attenuation of atrophy through effects on the ubiquitin-proteasome pathway. T Yimlamai SL Dodd SE Borst S Park, J Appl Physiol 2005 99 71 80 10.1152/japplphysiol.00448.2004 15774696
90. Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats. JG Ryall DR Plant P Gregorevic MN Sillence GS Lynch, J Physiol 2004 555 175 188 14617677 10.1113/jphysiol.2003.056770
91. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. S Busquets MT Figueras G Fuster V Almendro R Moore-Carrasco E Ametller JM Argiles FJ Lopez-Soriano, Cancer Res 2004 64 6725 6731 10.1158/0008-5472.CAN-04-0425 15374990
92. Clenbuterol ingestion causing prolonged tachycardia, hypokalemia, and hypophosphatemia with confirmation by quantitative levels. RJ Hoffman RS Hoffman CL Freyberg RH Poppenga LS Nelson, J Toxicol Clin Toxicol 2001 39 339 344 10.1081/CLT-100105152 11527226
93. Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation. SM Wyke ST Russell MJ Tisdale, Br J Cancer 2004 91 1742 1750 15477867
94. Sepsis-induced muscle proteolysis is prevented by a proteasome inhibitor in vivo. D Fischer G Gang T Pritts PO Hasselgren, Biochem Biophys Res Commun 2000 270 215 221 10.1006/bbrc.2000.2398 10733930
95. Proteasome inhibition in multiple myeloma: therapeutic implication. D Chauhan T Hideshima KC Anderson, Annu Rev Pharmacol Toxicol 2005 45 465 476 10.1146/annurev.pharmtox.45.120403.100037 15822185
96. Disuse atrophy and exercise rehabilitation in humans profoundly affects the expression of genes associated with the regulation of skeletal muscle mass. SW Jones RJ Hill PA Krasney B O'Conner N Peirce PL Greenhaff, Faseb J 2004 18 1025 1027 15084522
97. The AP-1/cJUN signaling cascade is involved in muscle differentiation: implications in muscle wasting during cancer cachexia. R Moore-Carrasco, FEBS Lett 2006 580 691 696 10.1016/j.febslet.2005.12.084 16412434
98. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. YP Li Y Chen J John J Moylan B Jin DL Mann MB Reid, Faseb J 2005 19 362 370 10.1096/fj.04-2364com 15746179
99. Drug discovery in the ubiquitin-proteasome system. G Nalepa M Rolfe JW Harper, Nat Rev Drug Discov 2006 5 596 613 10.1038/nrd2056 16816840
100. Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia. J Khal SM Wyke ST Russell AV Hine MJ Tisdale, Br J Cancer 2005 93 774 780 10.1038/sj.bjc.6602780 16160695
101. Sepsis upregulates the gene expression of multiple ubiquitin ligases in skeletal muscle. CJ Wray JM Mammen DD Hershko PO Hasselgren, Int J Biochem Cell Biol 2003 35 698 705 10.1016/S1357-2725(02)00341-2 12672461
102. Muscle wasting in a rat model of long-lasting sepsis results from the activation of lysosomal, Ca2+-activated, and ubiquitin-proteasome proteolytic pathways. L Voisin D Breuille L Combaret C Pouyet D Taillandier E Aurousseau C Obled D Attaix, J Clin Invest 1996 97 1610 1617 8601625
103. Regulation of proteolysis during reloading of the unweighted soleus muscle. D Taillandier E Aurousseau L Combaret CY Guezennec D Attaix, Int J Biochem Cell Biol 2003 35 665 675 10.1016/S1357-2725(03)00004-9 12672458
104. Differential gene expression profiling of short and long term denervated muscle. J Batt J Bain J Goncalves B Michalski P Plant M Fahnestock J Woodgett, Faseb J 2006 20 115 117 16291642
105. Ubiquitin conjugation by the N-end rule pathway and mRNAs for its components increase in muscles of diabetic rats. SH Lecker V Solomon SR Price YT Kwon WE Mitch AL Goldberg, J Clin Invest 1999 104 1411 1420 10562303
106. Proteomic analysis of altered protein expression in skeletal muscle of rats in a hypermetabolic state induced by burn sepsis. X Duan F Berthiaume D Yarmush ML Yarmush, Biochem J 2006 397 149 158 16483253 10.1042/BJ20051710
107. Post burn muscle wasting and the effects of treatments. C Pereira K Murphy M Jeschke DN Herndon, Int J Biochem Cell Biol 2005 37 1948 1961 10.1016/j.biocel.2005.05.009 16109499
108. Activation of ubiquitin-proteasome pathway is involved in skeletal muscle wasting in a rat model with biliary cirrhosis: potential role of TNF-alpha. SY Lin WY Chen FY Lee CJ Huang WH Sheu, Am J Physiol Endocrinol Metab 2005 288 E493 501 10.1152/ajpendo.00186.2004 15522995
109. Skeletal muscle atrophy is associated with an increased expression of myostatin and impaired satellite cell function in the portacaval anastamosis rat. S Dasarathy M Dodig SM Muc SC Kalhan AJ McCullough, Am J Physiol Gastrointest Liver Physiol 2004 287 G1124 1130 10.1152/ajpgi.00202.2004 15256363
110. Ubiquitin-proteasome-dependent muscle proteolysis responds slowly to insulin release and refeeding in starved rats. AJ Kee L Combaret T Tilignac B Souweine E Aurousseau M Dalle D Taillandier D Attaix, J Physiol 2003 546 765 776 10.1113/jphysiol.2002.032367 12563002
111. Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. JM Argiles S Busquets C Garcia-Martinez FJ Lopez-Soriano, Nutrition 2005 21 977 985 16043325
112. The ubiquitin-proteasome proteolytic pathway in heart vs skeletal muscle: effects of acute diabetes. Z Liu WR Miers L Wei EJ Barrett, Biochem Biophys Res Commun 2000 276 1255 1260 10.1006/bbrc.2000.3609 11027619
113. Identification of pathways controlling muscle protein metabolism in uremia and other catabolic conditions. J Du WE Mitch, Curr Opin Nephrol Hypertens 2005 14 378 382 15931008
114. Inactivation of the HR6B ubiquitin-conjugating DNA repair enzyme in mice causes male sterility associated with chromatin modification. HP Roest J van Klaveren J de Wit CG van Gurp MH Koken M Vermey JH van Roijen JW Hoogerbrugge JT Vreeburg WM Baarends D Bootsma JA Grootegoed JH Hoeijmakers, Cell 1996 86 799 810 10.1016/S0092-8674(00)80154-3 8797826
115. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. S Messina A Bitto M Aguennouz L Minutoli MC Monici D Altavilla F Squadrito G Vita, Exp Neurol 2006 198 234 241 10.1016/j.expneurol.2005.11.021 16410003
116. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. Y Kamei S Miura M Suzuki Y Kai J Mizukami T Taniguchi K Mochida T Hata J Matsuda H Aburatani I Nishino O Ezaki, J Biol Chem 2004 279 41114 41123 10.1074/jbc.M400674200 15272020